key: cord-0935135-hem0y9uq
authors: Galimberti, Fabrizio; McBride, Jeffrey; Cronin, Megan; Li, Yumeng; Fox, Joshua; Abrouk, Michael; Herbst, Alexander; Kirsner, Robert S.
title: Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19()()()
date: 2020-05-14
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.05.003
sha: cd4323398fcd68915291d7b9203268db7931cf3c
doc_id: 935135
cord_uid: hem0y9uq

The emergence of the COVID-19 pandemic led to significant uncertainty among physicians and patients about the safety of immunosuppressive medications used for the management of dermatologic conditions. We review available data on commonly used immunosuppressants and their effect on viral infections beyond COVID-19. Notably, the effect of some immunosuppressants on viruses related to SARS-CoV2, including SARS and MERS, has been previously investigated. In the absence of data on the effect of immunosuppressants on COVID-19, these data could be used to make clinical decisions on initiation and continuation of immunosuppressive medications during this pandemic. In summary, we recommend considering the discontinuation of oral JAK inhibitors and prednisone, considering the delay of rituximab infusion, and the careful continuation of cyclosporine, mycophenolate, azathioprine, methotrexate, and biologics in patients currently benefitting from such treatments.

Infectious diseases continue to pose significant challenges to public health. The first cases of respiratory infections of unknown origin emerged in Hubei province (Wuhan, China) in December 2019. The WHO officially announced on February 11, 2020 that the outbreak is caused by the novel enveloped RNA betacoronavirus that has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while its associated disease has been named coronavirus disease 2019 (Covid-19) 1 . SARS-CoV-2 shares phylogenetic similarities with other coronaviruses, including the one responsible for the severe acute respiratory syndrome coronavirus (SARS-CoV) 2 . COVID-19 has quickly turned into a global pandemic, unprecedented in the modern world. As immunosuppressive drugs are prescribed to a greater number of patients, concern exists for increased morbidity and mortality in patients infected with COVID-19 treated with these medications. Here we review evidence evaluating commonly used immunosuppressants medication in dermatology with regards to viral infections.

Cyclosporine A (CsA) is a small molecule that binds to members of the cyclophilin family. Cyclophillins are involved in protein folding and their inhibition results in inhibition of calcineurin and the nuclear factor of activated T cells (NF-AT) 3 . CsA has been linked to significant risk of serious infection in psoriasis patients (RR= 3.12) , greater compared to other immunosuppressants, particularly biologics 4 . Similarly, psoriasis patients on CsA are known to have higher incidence of herpes zoster 5 . Additionally, CsA has been shown to decrease immune response to influenza vaccination at high doses 6 . The duration of CsA effects on the immune system is currently unknown, however, in vivo animal models found full recovery within 4 days of last dose 7 .

CsA is known to interfere with replication of diverse viruses, including the human immunodeficiency virus 8 , flaviviruses 9 , and hepatitis C 10 . Intriguingly, CsA has also been shown Journal Pre-proof J o u r n a l P r e -p r o o f to inhibit replication of coronaviruses: CsA inhibits replication of MERS 11 , SARS 12 , shuman   CoV-229E, -NL-63, feline CoV, and avian infectious bronchitis virus 13, 14 . Similar results were seen with non-immunosuppressive CsA derivatives, such as Alispovir 15 , and medications targeting FK506 16(p50) . More data are needed to evaluate the magnitude of increased risk for viral infections, specifically COVID-19, in patients taking CsA. Similarly, more data are needed to evaluate if a possible therapeutic role exists for CsA in patients with COVID-19. Based on limited data, for patients who are not infected with COVID-19 and who have stable control of their dermatologic disease, we suggest not to preemptively discontinue or decrease CsA. Patients on CsA should immediately report any flu or cold-like symptoms to their physicians. For patients with a high degree of suspicion or diagnosed with active COVID-19 infection, we recommend temporary cessation of CsA. Additionally, we recommend care when initiating CsA at this time unless there are no other alternatives; taking into account the risk, benefits, and temporary delay of initiation with patients in non-epidemic and epidemic COVID-19 areas.

Mycophenolate mofetil (MMF) is a FDA-approved immunosuppressant for renal allograft rejection 3 . MMF is a noncompetitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase 17 , resulting in the inhibition of lymphocyte proliferation and antibody production 3, 18 . Indeed, MMF decreased immune response to influenza vaccine 19 

Glucocorticoids result in decreased production of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), prostaglandins, and leukotrienes, while increasing anti-inflammatory cytokines 22, 23 and decreasing inflammatory cytokines 24 . Infections are a well-characterized complication of steroids. A meta-analysis evaluating 71 controlled trials found significantly increased infection rate in patients receiving corticosteroids 25 . Additionally, although dose less than 20mg daily are not considered sufficiently immunosuppressive to preclude live vaccinations, treatment discontinuation of 1 to 3 months is recommended prior to live vaccinations for patients on higher daily doses 26 . Although there is no clear evidence of effects of prednisone on SARS-CoV-2, prednisone has been linked to unfavorable clinical outcomes in other viral infections. For example, prednisone was found to result in significantly higher incidence of severe acute respiratory infections (SARI) in pH1N1 patients as well as an increased risk of subsequent critical illness or death. Interestingly, patients who were given corticosteroids after the onset of SARI did not have worse outcomes 27 . Prednisone is known to be beneficial in management of some viral infections: for example prednisone used with acyclovir decreases pain in herpes zoster 28 . Intriguingly, use of steroids in herpes zoster patients has shown to lead to decreased level of IL-6 29 , an inflammatory cytokine known to be significantly upregulated and a possible therapeutic target in COVID-19 30 

Azathioprine (AZA) is a moderately potent immunosuppressive agent. AZA and its active metabolite 6-thioguanine (6-TG), a purine analogue, suppresses T-cell function and B-cell antibody production 18 . AZA has been uncommonly associated with opportunistic infections 3 .

Although the duration of AZA effects on the immune system is unclear, hematopoietic recovery was observed after at least 40 days from last dose in CD-1 mice 34 . Use of AZA at dosage ≤3 mg/kg is not sufficiently immunosuppressive to preclude live vaccines 26 Based on limited data, for patients who are not infected with COVID-19 and who have stable control of their dermatologic disease, we suggest not to discontinue or decrease AZA preemptively. Patients on AZA should immediately report any fever, flu, or cold-like symptoms to their physicians and for patients with a high degree of suspicion or who are diagnosed with active COVID-19 infections, we recommend temporary cessation of their AZA or the initiation of AZA inhibitors in COVID-19 epidemic and non-epidemic areas.

Rituximab is an immunoglobulin-G1 (IgG1) monoclonal antibody that targets CD20 

Interferons (IFN) play a crucial role in the immune response to viruses. Binding of type I IFN to its receptor lead to activation of JAK kinases which then activate the STAT transcription factors to upregulate antiviral immunity 49 . Selective JAK-inhibitors (JAKi), including ruxolitinib and tofacitinib, are now being used in dermatology. A protective role for IFN-1 against coronaviruses, including SARS-CoV, has been previously elucidated in vitro 50 and in vitro 51 . Of particular concern, STAT-1 deficient mice are more susceptible and develop more severe and disseminated infection when exposed to SARS-CoV as compared to wild type mice 52, 53 . A possible role of IFN in the treatment of SARS has been previously suggested 54 . The potent immunosuppressive effects of tofacitinib were also shown by the almost double rate of herpes zoster among RA patients treated with tofacitinib as compared to those treated with biologics 55 .

Additionally, tofacitinib has been shown to decrease response to pneumococcal vaccination 56 .

Interruption of tofacitinib for 2 weeks improves response to vaccination 56 

Biologics revolutionized the management of numerous dermatologic conditions. With the COVID-19 pandemic, many patients and providers are understandably concerned about the immunomodulatory effects associated with injectable biologics 57 . In Table 1 , we compare the overall upper respiratory tract infection on published data from pivotal trials in FDA package inserts. While it is challenging to infer clinical decision making from this data in regards to COVID-19, it may be used to decide whether or not to continue injectable biologics during this pandemic. As shown in Table 1 , biologic injectables seem to carry minimal increased risk of infection. Additionally, it is important to consider that discontinuation of some biologics may result in loss of efficacy and formation of autoantibodies [58] [59] [60] . Thus, for patients who are not infected with COVID-19 and who have stable control of their dermatologic disease, we suggest not to preemptively discontinue or decrease biologic injectables. Patients on biologics should immediately report any fever, flu, or cold-like symptoms to their physicians and for patients with a high degree of suspicion or diagnosed with active COVID-19 infection, we recommend temporary cessation of their biologic injectables. Additionally, we recommend careful initiation of biologic injectables at this time unless there are no other alternatives taking into account and after careful discussion of risk, benefits, and temporary delay of initiation with patients in nonepidemic COVID-19 areas.

COVID-19 presents an unprecedented challenge to our modern society. A common concern is the continuation of immunosuppressants for dermatologic conditions. We reviewed the mechanism of action and evidence of increased infection associated with commonly prescribed immunosuppressants. Without specific data in the context of COVID-19, we have recommended considering discontinuation of oral JAKi and prednisone and careful continuation of other medications in patients currently benefitting from such treatments ( Table 2) . Available IgG could be used to safely reinstate or initiate immunosuppressants in COVID-19 epidemic and non-epidemic areas. 

Clinical Characteristics of Coronavirus Disease 2019 in China

A Novel Coronavirus from Patients with Pneumonia in China

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs

Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine

Recovery of T-cell function in healthy dogs following cessation of oral cyclosporine administration

Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1

Involvement of cyclophilin B in the replication of Japanese encephalitis virus

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha

Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

Suppression of Coronavirus Replication by Cyclophilin Inhibitors

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine Aderivatives including Alisporivir

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Mycophenolate Mofetil: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation

The Use of Systemic Immune Moderators in Dermatology: An Update

Influenza vaccination in solid-organ transplant recipients

Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses

Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus

Infection Risk and Safety of Corticosteroid Use

Regulation of cytokine and cytokine receptor expression by glucocorticoids

Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts

Risk of infectious complications in patients taking glucocorticosteroids

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study

Management of Herpes Zoster (Shingles) and Postherpetic Neuralgia

Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;0(0)

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): antiinflammatory strategies

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

On the use of corticosteroids for 2019-nCoV pneumonia

The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse

Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs

Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies

Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids

Azathioprine can be safely used in HIV-infected individuals

Predictors of major infections in systemic lupus erythematosus

The biology of CD20 and its potential as a target for mAb therapy

Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response

Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a casecontrol study in Asia

Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis

Mechanism of Action of Methotrexate Against Zika Virus

Flaviviruses Are Sensitive to Inhibition of Thymidine Synthesis Pathways

JAK inhibitors in dermatology: the promise of a new drug class

Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV

Treatment of SARS with human interferons

Real-World Comparative Risks of Herpes Virus Infections in Tofacitinib and Biologic-Treated Rheumatoid Arthritis Patients

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Should biologics for psoriasis be interrupted in the era of COVID-19?

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

J o u r n a l P r e -p r o o f